Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs Esketamine in Fibromyalgia
NCT04938713Unknown
- Sponsor
- CHU de Charleroi
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine and ketamine in fibromyalgia (FM), sponsored by CHU de Charleroi. Primary endpoint: Fibromyalgia Impact Questionnaire at Day 28. Status: unknown.
02
Drugs
esketamineketamine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04938713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938713.